KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial. PMID 39833645 · Pediatr Blood Cancer · 2025-Apr 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Accounting for differential exclusions in the Nordic-European initiative on colorectal cancer trial discloses stronger-than-reported effects of screening colonoscopy. PMID 39800010 · J Clin Epidemiol · 2025-Apr The study is a randomized trial in human colorectal cancer (oncology). It is an original report of primary results. However, it evaluates a screening intervention (colonoscopy), not a drug-containing intervention. Furthermore, the primary endpoints are cancer incidence and risk reduction (relative risk, odds ratio), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier analysis with hazard ratio. Phase is not specified as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Refining Risk Stratification for B-cell Precursor Adult Acute Lymphoblastic Leukemia Treated With a Pediatric-inspired Regimen by Combining IKZF1 Deletion and Minimal Residual Disease. PMID 39798801 · Transplant Cell Ther · 2025-Apr The record describes a non-randomized cohort study evaluating risk stratification and outcomes with a drug-containing chemotherapy regimen, but it lacks evidence of randomization between treatment arms. Eligibility requires a randomized trial, so it is excluded despite other criteria being met.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial. PMID 39791315 · Cancer Commun (Lond) · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Recurrence-free survival after hepatectomy using propofol-based total intravenous anaesthesia and sevoflurane-based inhalational anaesthesia: a randomised controlled study. PMID 39776101 · Anaesthesia · 2025-Apr 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer. PMID 39746162 · J Clin Oncol · 2025-Apr The abstract describes a long-term follow-up and biomarker subgroup analysis of the C9741 trial. While it reports overall results (improved DFS and OS for dose-dense chemotherapy), the stated primary purpose and conclusion center on identifying the biomarker-defined subgroup (SET2,3) that benefits, making the report type 'subgroup'. Furthermore, the trial phase is not explicitly stated in the provided metadata (title, abstract, publication types, MeSH), preventing confirmation of the required Phase III/IIIb or Phase II/III criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial. PMID 39707623 · Clin Pharmacol Ther · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of an Endoscopy Screening on Upper Gastrointestinal Cancer Mortality: A Community-Based Multicenter Cluster Randomized Clinical Trial. PMID 39706350 · Gastroenterology · 2025-Apr The study is a randomized, oncology trial reporting a primary result, but it is excluded because the intervention is non-drug (endoscopic screening) and the outcome is not a standard time-to-event efficacy endpoint (e.g., OS, PFS) as defined by the inclusion criteria. No phase information is provided to confirm it is a Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. PMID 39700456 · J Clin Oncol · 2025-Apr The study is a Phase III, randomized-controlled trial (RCT) of a drug in oncology, but it is a single-arm trial and the primary endpoint is objective response rate (ORR), not a time-to-event endpoint like OS, PFS, or DFS. The abstract does not report Kaplan-Meier curves or hazard ratios for any time-to-event outcome. Therefore, it does not meet the core requirement for a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Laparoscopic suture-free partial nephrectomy using argon-beam-coagulator: Surgical technique and outcomes of a single-center, open-label randomized controlled trial. PMID 39578201 · Urol Oncol · 2025-Apr 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer. PMID 39545921 · Mol Oncol · 2025-Apr The record describes a biomarker-focused secondary analysis of the ALICE trial, investigating the prognostic and predictive value of gut microbiota. While it references a randomized trial with a drug intervention and a PFS endpoint, the abstract does not state the trial's phase, and the report's primary focus is not the formal reporting of the trial's primary efficacy results. Therefore, it does not meet the criteria for an original, primary result report of a definitive-phase trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec. PMID 39406613 · Eur Urol Oncol · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Health-related quality of life in cutaneous T-cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome. PMID 39315857 · J Eur Acad Dermatol Venereol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial. PMID 38764430 · J Chemother · 2025-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial. PMID 38688767 · Eur Urol Oncol · 2025-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Atorvastatin and left atrial function during anthracycline-based chemotherapy. PMID 40876541 · J Cardiovasc Magn Reson · 2025 Win 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effectiveness of Integrated Mindfulness-Based Fitness Training Program in Ameliorating Physical Symptoms and Survivor Concerns in Patients With Breast Cancer: A Randomized Clinical Trial. PMID 38158601 · Cancer Nurs · 2025 May The study is a randomized controlled trial in oncology (breast cancer) but does not meet key eligibility criteria: it lacks a drug intervention, is not definitively a Phase III/IIIb or Phase II/III trial, and does not report a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Experimental Study of Ultra-Pulsed CO 2 Fractional Laser Combined With Recombinant Human Epidermal Growth Factor Gel in the Treatment of Eyelid Keloid. PMID 39197180 · Ophthalmic Plast Reconstr Surg · 2025 Mar The record describes a randomized trial of a drug-containing intervention (rHEGF gel) for eyelid keloid, which is not a malignant neoplasm. Furthermore, it lacks the required time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Recent Advancements and Future Perspectives on Molecular Biomarkers in Adult Lower-Grade Gliomas. PMID 39841423 · Cancer J · 2025 Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Ablatio-bilica: safety of biliary intraductal radiofrequency ablation in patients with unresectable extrahepatic biliary tract cancer undergoing systemic anti-tumor therapy: a phase II, multi-center, randomized, and controlled study. PMID 41816011 · Front Oncol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Target trial emulation in oncology: current use and future directions. PMID 41810148 · Mil Med Res · 2025 This is a review article discussing the use and challenges of target trial emulation in oncology. It is not a primary result report of an individual, randomized, drug-intervention Phase III trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multimodal prehabilitation enhances perioperative outcomes in gastric cancer patients: a single-center randomized controlled trial. PMID 41710593 · Front Nutr · 2025 The record describes a randomized trial of a non-drug, multimodal prehabilitation (exercise, nutrition, psychological support) for gastric cancer patients undergoing surgery. The primary endpoint is 30-day complication rate, with secondary endpoints of functional recovery and patient-reported outcomes. There is no drug intervention, and no time-to-event efficacy endpoint (OS, PFS, DFS, etc.) is reported. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial. PMID 41647109 · Front Endocrinol (Lausanne) · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China. PMID 41601703 · Front Urol · 2025 干预为非药物单独策略,未满足药物干预要求。
H B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial. PMID 41601631 · Front Immunol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Incidence and risk assessment of thyroid dysfunction following immune checkpoint inhibitor therapy: a systematic review and meta-analysis. PMID 41552314 · Am J Transl Res · 2025 The record is a systematic review/meta-analysis of phase II/III RCTs. While it synthesizes data from multiple oncology trials with drug interventions, it is not an original trial report itself. Furthermore, its outcome of interest (incidence of thyroid dysfunction) is a safety/toxicity endpoint, not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the inclusion criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of a pubic superior ramus approach versus a distal approach for obturator nerve block in transurethral bladder tumor resection: a randomized controlled trial. PMID 41552287 · Am J Transl Res · 2025 The study is an oncology RCT in humans with a primary result, but it does not meet all required eligibility criteria: (1) the trial phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata; (2) the intervention is a surgical/anesthetic technique (obturator nerve block approach) without a drug-containing intervention as the primary comparator; (3) the primary efficacy endpoint is not a time-to-event endpoint. Therefore, is_eligible is false.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
From trial to real life: ten-year impact of a nutraceutical strategy on duodenal polyp burden in familial adenomatous polyposis. PMID 41551144 · Front Oncol · 2025 The study is a prospective cohort, not a randomized trial, and evaluates a nutraceutical supplement with continuous outcomes (polyp burden), lacking the required randomized drug intervention and time-to-event endpoint for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. PMID 41550955 · Front Immunol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dose-enhanced versus standard TTFields for first recurrence of glioblastoma: A randomized phase 2 clinical trial. PMID 41473750 · Neurooncol Adv · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Intratumoral delivery of PD-1/PD-L1 and CTLA-4 inhibitors for recurrent/refractory solid tumors: a proof-of-concept treatment strategy. PMID 41459523 · Front Immunol · 2025 This is a Phase II/III clinical trial (per publication_types) of intratumoral immune checkpoint inhibitors in recurrent/refractory solid tumors, which is oncologic, human, and involves a drug intervention with original results. However, it is not randomized (no mention of randomization) and lacks a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR reporting. The abstract reports only four cases with complete responses, which is not a formal time-to-event analysis from a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of a Short-Term Advance Care Planning Intervention (VOICE) for Dialysis Patients with ESRD: A Randomized Controlled Trial. PMID 41459036 · Patient Prefer Adherence · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Home-Combo: an online home-based exercise intervention for women with breast cancer undergoing neoadjuvant chemotherapy: study protocol for a 2-arm pragmatic randomized controlled trial. PMID 41458599 · Front Oncol · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Teaching Cancer Survivors Coping Skills for Managing Fear of Recurrence: Insights From a Pilot Randomized Controlled Trial. PMID 41445966 · Glob Adv Integr Med Health · 2025 This is an oncology, human, randomized, original result report, but it is excluded because it is not a Phase III/IIIb or Phase II/III trial (phase is not specified and not a drug trial), it has no time-to-event efficacy endpoint (outcomes are coping scores, not OS/PFS/DFS/EFS/RFS/TTP, and no Kaplan-Meier/HR reported), and it lacks a drug-containing intervention (intervention is a mind-body psycho-oncology program, not a drug).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Integrating smoking cessation support during lung cancer diagnostic workup: a pragmatic, multicenter, cluster-randomised controlled trial. PMID 41445708 · Front Health Serv · 2025 The trial is a randomized study in human lung cancer patients with original results, but it is not eligible because it lacks a drug-containing intervention and does not have a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The phase is also not established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Testing oral nicotine pouches versus nicotine replacement therapy for cigarette harm reduction in Appalachia: The ARISE study protocol. PMID 41433314 · PLoS One · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clostridium butyricum MIYAIRI 588 Reduces Colorectal Adenomatous Polyp Recurrence: A Randomized Crossover Trial. PMID 41425719 · Oncol Res · 2025 The study does not meet the core eligibility criteria: it is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Landscape Analysis of Human Papillomavirus (HPV) Prophylactic Vaccine Clinical Trials in China Based on the NMPA Database. PMID 41425496 · Drug Des Devel Ther · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Effect of Opioid-Free Anesthesia with Esketamine on Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Thoracoscopic Surgery: A Prospective, Randomized, Controlled Trial. PMID 41425495 · Drug Des Devel Ther · 2025 The record describes a randomized trial in lung cancer patients, but it fails two key eligibility criteria: (1) the primary endpoint is not a time-to-event efficacy endpoint (it is the incidence of a postoperative complication), and (2) there is no explicit evidence of a Phase III/IIIb or Phase II/III trial design. Therefore, it is not eligible for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effects of narrative care combined with life review on psychological distress, meaning in life, and quality of life in advanced cancer patients receiving hospice care: a randomized clinical trial. PMID 41409070 · Front Psychol · 2025 The record describes a randomized trial of a psychosocial intervention (narrative care combined with life review) in advanced cancer patients. While it is oncology-related, human, and randomized, it lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The outcomes assessed are psychological distress, meaning in life, and quality of life.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Mechanism of an integrated PBL-KAP-AI spiral health education model for breast cancer patients. PMID 41404555 · Front Public Health · 2025 The study is a randomized trial in oncology (breast cancer) with original results. However, it is excluded because it is not a Phase III/IIIb or Phase II/III trial (phase is not specified and cannot be inferred), it does not involve a drug-containing intervention (it evaluates a health education model), and its primary outcomes (health behaviors, beliefs, quality of life) are not time-to-event endpoints (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of preoperative oral carbohydrate combined with postoperative early enteral nutrition on the perioperative rehabilitation of patients with colorectal cancer: a multicenter randomized controlled trial. PMID 41393952 · Front Nutr · 2025 The study is a randomized trial in colorectal cancer patients. It reports on perioperative recovery outcomes (e.g., time to first exhaust, hospitalization length) but does not report on a time-to-event efficacy endpoint such as OS, PFS, DFS, or Kaplan-Meier survival analysis. The intervention (preoperative oral carbohydrates and postoperative early enteral nutrition) is non-drug, not a therapeutic anti-neoplastic drug. The trial phase is not specified in the record.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effects of Different Doses of Butorphanol on Perioperative Analgesia, Recovery, and Immune Function in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer: A Randomized Controlled Trial. PMID 41393328 · Drug Des Devel Ther · 2025 The study is a randomized trial of a drug for perioperative pain management in ovarian cancer surgery, but it does not meet key eligibility criteria: it is not a Phase III/IIIb or Phase II/III trial, and it lacks a time-to-event oncology efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma. PMID 41383547 · Blood Lymphat Cancer · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Research trends in neoadjuvant therapy for esophageal cancer: a bibliometric and meta-analysis. PMID 41346615 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A phase II clinical trial of Bifidobacterium longum subsp. longum BL21 for preventing acute radiation enteritis among pelvic radiotherapy patients. PMID 41293184 · Front Nutr · 2025 The study is a phase II, single-arm, non-randomized trial evaluating a probiotic for toxicity prevention, lacking the required phase, randomization, drug intervention, and time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prophylactic effect of the traditional Chinese medicine formula danxiong granules (TDX105) on hand-foot skin reaction associated with the antitumor targeted drug regorafenib: a randomized, double-blind, placebo-controlled trial. PMID 41282614 · Front Pharmacol · 2025 The record does not provide explicit evidence that the trial is Phase III/IIIb or Phase II/III, which is a required criterion for eligibility. Furthermore, the primary endpoint is not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Although PFS is reported, its status as a primary or key secondary endpoint is not confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effects of Growth hormone treatment discontinuation in Adults on Metabolic profile, Body composition and quality Of Life (GAMBOL Study). PMID 41262296 · NIHR Open Res · 2025 未发现恶性肿瘤人群证据。
H B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Nurse led telephonic palliative care versus specialty outpatient palliative care: pragmatic, randomised clinical trial. PMID 41245582 · BMJ Med · 2025 The study is a randomized clinical trial with oncology patients (advanced cancer) and reports primary results, but it is ineligible because it lacks a drug-containing intervention (interventions are palliative care delivery models) and does not report a time-to-event efficacy endpoint. The primary outcome is change in quality of life (FACT-G score), not a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effectiveness of kinesiology taping on dysphagia in brain tumor survivors after neurosurgery: study protocol for a pilot randomized controlled trial. PMID 41244764 · Front Med (Lausanne) · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -